Ubrogepant

Migraine Disorder

H. Lundbeck A/SSmall moleculePhase 4 / ApprovedActive

BBB

79/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 83/ 100
Competitive Position: 73/ 100

Competitive context

100 Active assets in the Migraine Disorder cohort.

Asset / Sponsor	Phase	Rating
Atogepant Stanford University	Phase 4	A
Zolmitriptan Zosano Pharma Corporation	Phase 4	A
Naproxen IRCCS San Raffaele Roma	Phase 4	A
Rizatriptan Antonios Likourezos	Phase 4	A
DFN-11 (SUMATRIPTAN INJECTION) IRCCS San Raffaele Roma	Phase 4	BBB

View all 50 →

Same molecule, other indications

Ubrogepant is also rated in:

migraine without auraActive

BB

Indicative · Phase 4

65 / 100

migraine with auraActive

B

Indicative · Phase 4

62 / 100

overactive bladderActive

D

Indicative · Unknown

30 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.